COLUMBUS, Ohio - Wednesday, 21. October 2026
Expanded collaboration brings advanced runway safety training to HondaJet pilots
(BUSINESS WIRE) -- FlightSafety International Inc. (FSI), the global leader in aviation training and simulation technology, today announced an expansion of its longstanding partnership with Honda Aircraft Company to provide a new Runway Operations Mastery course for HA-420 Elite and Elite II pilots.
Developed in collaboration with Honda Aircraft Company, the immersive training course focuses on strengthening pilot proficiency to support safer operations. The new voluntary offering reflects the companies’ shared commitment to advancing aviation safety through specialized training.
“For more than 75 years, FlightSafety’s mission has been to advance aviation safety through training that addresses real-world challenges pilots face,” said Ben Carter, Executive Vice President, Learning Center Operations, FlightSafety International. “This new course reflects our ongoing commitment to working with our OEM partners to deliver specialized training that reinforces critical skills to support more confident decision-making in challenging conditions.”
“As part of our broader commitment to deliver an exceptional ownership experience well beyond aircraft delivery, we are equipping HondaJet operators with additional tools and knowledge to build confidence, enhance proficiency, enhance operational readiness and maximize the performance of their aircraft,” said Amod Kelkar, Senior Vice President and Chief Commercial Officer, Honda Aircraft Company. “We’re proud to partner with FlightSafety to support our operators with this industry-leading training.”
The 5.5-hour course combines eLearning, briefing and debriefing sessions, and Level D Full-Flight Simulator training. It is available by request in Greensboro, North Carolina, and Farnborough, United Kingdom. In the coming weeks, FSI's sales team will be reaching out to HondaJet operators with information about the new course, including a special introductory promotional offer available for a limited time. Operators interested in learning more are encouraged to contact their FlightSafety representative.
About FlightSafety International Inc.
FlightSafety International is the world’s preeminent professional aviation training company and supplier of flight simulators, visual systems, and displays to educational, commercial, government, and military organizations. In 2026, the company celebrates its 75th anniversary, marking more than seven decades of advancing aviation safety through rigorous, real-world training programs delivered to pilots, technicians, and other professionals from 170+ countries. FSI currently operates a global fleet of advanced simulators at learning centers and training locations on six continents. For more information, please visit flightsafety.com.
About Honda Aircraft Company
Honda Aircraft Company is a wholly owned subsidiary of American Honda Motor Co., Inc. responsible for the research, development, sales, marketing, customer service, and manufacture of the innovative HondaJet Elite II. Founded in 2006, Honda Aircraft's world headquarters is located in North Carolina. Global deliveries of the HondaJet surpassed the 250-mark in 2024. The company is now developing its newest aircraft, the 11-occupant HondaJet Echelon, which will be produced in North Carolina alongside the HondaJet Elite II, as Honda Aircraft continues to advance the global Honda brand slogan “The Power of Dreams: How We Move You.” Learn more with the Honda Digital FactBook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261020467582/en/
Permalink
https://www.aetoswire.com/en/news/2110202658274
Contacts
Media Contact
FSI Press Team
fsipress@apcoworldwide.com
Tuesday, November 3, 2026
Senegal makes history as President Faye opens first Youth Olympic Games on African soil
Senegal made history on Saturday as President Bassirou Diomaye Faye officially opened the Dakar 2026 Youth Olympic Games, marking the first time the international youth sporting event has been held on African soil.
The opening ceremony took place on 31 October at the 50,000-capacity Abdoulaye Wade Stadium in Diamniadio, featuring 1,115 performers, including 628 dancers, in a celebration of Senegalese culture and African heritage.
The fourth edition of the Summer Youth Olympic Games runs until 13 November, bringing together approximately 2,650 athletes aged 14 to 17 from 204 National Olympic Committees, alongside the Refugee Olympic Team.
Dakar follows three previous host cities: Singapore in 2010, Nanjing in China in 2014 and Buenos Aires in Argentina in 2018. Senegal was selected to host the 2026 edition at the International Olympic Committee (IOC) Session in Buenos Aires in October 2018.
The sporting programme features 25 competition sports and 153 medal events, alongside 10 engagement sports. Competitions are taking place across three locations: Dakar, Diamniadio and Saly.
Dakar 2026 is also the first edition of the Youth Olympic Games to achieve full gender parity across athlete quota places, sports, disciplines and events. The programme includes 73 women's events, 73 men's events and seven mixed events.
Another milestone is the participation of a six-member Refugee Olympic Team, comprising athletes based in Africa. It is the first time a Refugee Olympic Team has competed at the Youth Olympic Games.
"Hosting the first Youth Olympic Games in Africa is a historic milestone for Senegal and the continent. Dakar 2026 provides an opportunity to welcome young athletes from across the world, showcase Africa's sporting talent and cultural heritage, and inspire a new generation to participate in sport. We hope the Games will leave a lasting legacy by creating greater opportunities for young people and strengthening the development of sport across the continent," the Dakar 2026 Youth Olympic Games Organising Committee said.
For more information, visit www.dakar2026.org
Contacts
Sudhashree Dash, Sudha@memc.co
TVS Motor Company Strengthens Its European Presence With Four Production-Ready Models at EICMA 2026
SINGAPORE & MILAN - Tuesday, 03. November 2026 AETOSWire Print
TVS Motor expands its European presence through dedicated engineering facilities, a strengthened retail network and products developed for local customer needs
Four production-ready models broaden the company's offering across electric mobility, premium urban transportation and lightweight sports motorcycling
Global manufacturing scale, technology expertise and international engineering capabilities provide the foundation for TVS Motor's long-term success in Europe
(BUSINESS WIRE) -- TVS Motor Company, the world's third-largest two-wheeler manufacturer, today unveiled four production-ready models at EICMA 2026 in Milan, reinforcing its commitment to Europe as a strategic market. The showcase highlights products developed for European customers, supported by dedicated engineering capabilities, an expanding retail network, and the strengths of TVS Motor's global manufacturing, technology and product development ecosystem.
The four models, the TVS Orbiter, TVS M1-S, TVS X and TVS RTR 125, reflect TVS Motor's approach to serving Europe's evolving mobility needs across electric commuting, premium urban transportation and lightweight sports motorcycling. Together, they demonstrate the company's ability to combine market-specific product development with global engineering expertise and manufacturing excellence.
Europe plays an increasingly important role in TVS Motor's international business as the company continues to strengthen its presence in developed markets. Building on decades of manufacturing expertise, advanced technology capabilities and a growing international engineering footprint, TVS Motor is creating the foundations for sustainable long-term success in the region. This strategy also reflects the company's objective to increase the contribution of international business to its overall revenue, with the potential to reach 30% or more by 2030.
Peyman Kargar, President, International Business, TVS Motor Company, said: “Europe is an important market for TVS Motor and a key part of our international growth plans. We see significant opportunities across electric mobility, performance motorcycles and premium urban transportation. Success in these markets requires more than a competitive product. It requires a deep understanding of customer needs, strong local execution and a robust distribution and service network. Over the past year, we have focused on strengthening our distribution footprint, developing our dealer and service capabilities and preparing a portfolio suited to European riding needs. As we continue to strengthen our presence in Europe, our focus is on expanding customer access to the TVS brand, deepening customer engagement and delivering products that combine quality, technology and customer experience."
Peyman Kargar, who has more than three decades of international automotive leadership experience, has been appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027. He will succeed K. N. Radhakrishnan.
Europe: A strategic market for TVS Motor
TVS Motor's approach to Europe is centred on three priorities: developing products aligned to local customer needs and matched to European riding conditions, establishing strong distribution and aftersales capabilities, and leveraging its international engineering and design ecosystem to compete in technologically advanced markets.
The company has steadily expanded its retail presence, beginning with Italy and extending into Spain and Portugal, with further development planned in France and Germany. Its Italian network now comprises more than 100 retailers, supported by encouraging sales momentum. Sales in Italy have increased by 110 per cent over the past year, while an additional 22 retailers are operational across Spain and Portugal.
This expansion reflects TVS Motor's focus on building a sustainable business beyond initial product launches. The company continues to invest in market development, dealer capabilities and aftersales support, to ensure strong customer relationships and to establish trust and long-term brand consideration across European markets.
A market specific portfolio for Europe's evolving mobility needs
The four models presented at EICMA 2026 are designed to address distinct customer segments. The electric range spans everyday city commuting, more versatile urban transportation and premium connected mobility, while the TVS RTR 125 extends the company's sports motorcycle offering to younger and first-time riders.
TVS Motor's electric mobility experience provides the foundation for this expansion. With more than one million electric scooters sold globally and investments exceeding $1 billion in electric vehicle and battery ecosystems, the company is applying its experience in EV engineering, software integration and manufacturing to products developed for international markets.
TVS Orbiter: Making every day electric mobility more accessible
TVS Orbiter is positioned as a practical electric mobility solution for European urban commuters seeking convenience, manageable running costs and the flexibility to meet every day travel requirements.
Designed for city environments, TVS Orbiter combines compact urban mobility with functional features suited to regular commuting, short journeys and daily errands. Its upright riding position and 34-litre underseat storage support everyday usability, while the removable battery arrangement offers flexibility for customers who may not have access to dedicated parking or charging infrastructure.
The European-specification model offers two battery options – 1.8 kWh and 3.1 kWh – with expected WMTC ranges of 70 km and 105 km, respectively. Riders can charge the battery on the scooter or remove it for charging using a household power socket and dedicated dock.
With a top speed of 45 km/h, TVS Orbiter is positioned in Europe's L1e category, targeting riders who prioritise accessible, straightforward and efficient urban transportation.
TVS M1-S: Bringing electric mobility to the maxi-scooter segment
TVS M1-S addresses a different customer requirement: riders seeking the comfort, practicality and road presence of a maxi-scooter, combined with the benefits of an electric powertrain.
Positioned for commuters travelling across urban and suburban environments, the M1-S offers a more substantial riding experience than a conventional compact city scooter. Its design and engineering focus on comfort, performance and everyday versatility, making it relevant to customers considering an electric alternative to traditional mid-sized scooters.
The M1-S is powered by a 4.2 kWh battery and delivers 12.5 kW of peak power, enabling a top speed of 105 km/h. The battery is positioned low in the floorboard to optimise the centre of gravity and support stable, confident handling.
A 10–80% charge takes 75 minutes, while a 26-litre storage compartment accommodates a full-face helmet. Integrated LTE connectivity provides connected functionality without relying on a paired smartphone.
With this combination of practicality, performance and connectivity, the M1-S broadens TVS Motor's electric portfolio beyond short-distance commuting into a more versatile urban mobility category.
TVS X: Premium electric performance and connected technology
TVS X represents the premium, technology-led end of the company's European electric scooter portfolio. Designed for riders who value performance, advanced connectivity and distinctive engineering, the TVS X brings together electric powertrain technology, dynamic handling and a digitally integrated riding experience.
Positioned within the European A1 category, the TVS X is aimed at customers seeking an electric alternative to premium urban motorcycles and scooters without compromising on performance or technology.
Its European specification features 14-inch wheels at the front and rear, an aluminium frame and dual-channel ABS. The electric motor delivers 11.7 kW of peak power, enabling acceleration from 0–40 km/h in 2.5 seconds and a top speed of 110 km/h.
A 10.2-inch panoramic touchscreen integrates Android Auto and full-map navigation, supported by the scooter's independent LTE connectivity.
The TVS X demonstrates the company's approach to premium electric mobility, combining performance engineering with software-led functionality and a connected customer experience.
TVS RTR 125: Introducing a new generation to sports motorcycling
Complementing the three electric scooters, the RTR 125 strengthens TVS Motor's offering in Europe's lightweight performance motorcycle segment.
Developed for A1 licence holders, the RTR 125 targets younger riders and customers entering the performance motorcycle category who seek an engaging riding experience alongside the practicality required for everyday use.
The model draws on TVS Motor's performance engineering experience and the company's racing heritage, which dates back to 1982. It brings the principles of responsive performance, agility and rider control into an accessible 125 cc category.
TVS RTR 125 also serves as an entry point to TVS Motor's wider motorcycle portfolio in Europe, which includes the RR 310, RTR 310, Ronin and RTX 300. This range enables the company to address different stages of motorcycle ownership, from first-time performance riders to customers seeking more sophisticated sport, roadster and adventure motorcycles.
The RTX 300, introduced at EICMA 2025, is also scheduled to reach European dealerships, further expanding TVS Motor's presence in the adventure touring segment.
Global engineering capabilities supporting international commitment
TVS Motor's presence in Europe is supported by a global engineering and manufacturing ecosystem, with India playing a central role in product development, advanced engineering, manufacturing and quality.
The company's engineering ecosystem brings together capabilities across India, Singapore, the United Kingdom and Bologna, Italy. The establishment of its Global Centre of Excellence for Design and Engineering in Bologna, following the acquisition of Engines Engineering S.p.A., has further strengthened its ability to develop products for premium and technologically advanced markets.
This international engineering network allows TVS Motor to combine product development at scale with specialised expertise in design, electric powertrains, connected technologies and performance engineering. It also enables the company to incorporate customer and market requirements earlier in the product development process.
Showcasing the breadth of TVS Motor's global portfolio
The four production-ready models form part of TVS Motor's wider 19-vehicle showcase at EICMA 2026, reflecting the breadth of its portfolio across electric mobility, enthusiast motorcycles and premium riding experiences.
The display also includes the first global showing of the '82 Series, a collection of one-off editions of the RR 310, RTR 310, RTX 300 and Ronin, developed as a tribute to the company's racing heritage.
The '82 Series celebrates TVS Racing's contribution to the company's engineering philosophy and its commitment to transferring learning from motorsport into products for everyday riders.
TVS Motor will announce market-specific pricing, final specifications and availability dates for the four production-ready models closer to their respective European launches.
The TVS Motor stand is located in Hall 18, Stand I64, at Fiera Milano (Rho Fiera). EICMA 2026 opens to the public from November 5 to 8, with TVS Orbiter, M1-S and TVS X available for test rides in the designated test-ride area.
About TVS Motor Company
TVS Motor Company (BSE:532343 and NSE: TVSMOTOR), part of TVS VENU, is a reputed two and three-wheeler manufacturer globally, championing progress through sustainable mobility. Rooted in our 100-year legacy of trust, value, and passion for customers, it takes pride in making internationally accepted products of the highest quality through innovative and sustainable processes. TVS Motor is the only two-wheeler company to have won the prestigious Deming Prize. Our products lead in their respective categories in the J.D. Power IQS and APEAL surveys. We have been ranked No. 1 Company in the J.D. Power Customer Service Satisfaction Survey for four consecutive years. Our group company Norton Motorcycles, based in the United Kingdom, is one of the most emotive motorcycle brands in the world. TVS Motor Company endeavours to deliver the most superior customer experience across 90 countries in which we operate.
Website:
www.tvsmotor.com
Facebook:
https://www.facebook.com/tvsmotorcompany/
Instagram:
https://www.instagram.com/tvsmotorcompany
LinkedIn:
https://in.linkedin.com/company/tvs-motor-campany
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103474635/en/
Permalink
https://www.aetoswire.com/en/news/0311202658760
Contacts
Press contact
Kanika Mehta – International Business and Corporate: Kanika.Mehta@tvsmotor.com
David Rogers – EU and corporate: David.Rogers@tvsmotor.com
Stefania Gali – EU regional markets: Stefania.Gali@tvsmotor.com
KS Harini – Corporate & India: ks.harini@tvsmotor.com
SuperElastic* Material Unveiled by Angelalign
SAN CLEMENTE, Calif. - Tuesday, 03. November 2026
New, Improved Clear Aligner Material Gives Orthodontists More Control
(BUSINESS WIRE) -- Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material.
Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them.
“Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other treatments,“ said Fox Hu, CEO of Angel.
MC-SE will be available globally after the appropriate registrations are received.
A New Material For Complex Cases
Clear aligner materials determine how consistently forces are applied to teeth, how well they hold their shape over the course of wear, and how comfortable they are for patients.
Angel’s current material is a soft, multi-layered polymer, based on PETG material, designed to deliver gentle but long-lasting force. MC-SE is powered by a different material with significant improvements:
Gentle consistent force: engineered to deliver continuous force at biologically safe levels throughout the wear cycle.
Expanded elastic range: bends and stretches further than conventional materials and returns to its original shape, unlocking new clinical possibilities.
Superior elastic recovery: In three-point flexural testing at an eight percent strain, MC-SE springs back to its original flat shape. In contrast, samples of commonly used PETG and Angel’s current material remain visibly bent.
Structural strength and toughness: A medical grade polyamide layer within MC-SE‘s multi-layer structure adds strength and toughness.
Inspired by Clinical Traditions of the Orthodontic Specialty
Nickel-titanium (NiTi) archwires, valued by orthodontists for their low, continuous force, became the standard of care when using wires and brackets. Angel is honored to build on that tradition by unveiling MC-SE, which brings those properties to aligners.
The performance breakthrough is due to integration of medical grade polyamides into an aligner material. The polyamide family of materials, which includes kevlar and nylon, are utilized in extreme applications that demand elasticity, strength and toughness. MC-SE incorporates those attributes into a novel aligner material.
Aligners made with medical grade polyamides open exciting treatment possibilities. Angel will build this out as a material platform with different variations to achieve a variety of force effects.
“Angel innovation listens to orthodontists and analyzes case results. Clinicians send us a lot of complex cases,” said Richard Hirschland, Angel’s Chief Commercial Officer and SVP. “Aligner material is the foundation of every treatment. MC-SE gives orthodontists a stronger foundation to build on. It follows angelButtonTM, A6 Mandibular Advancement and Pressure Points as part of our commitment to continue developing clinical solutions for orthodontists.”
To learn more, visit www.angelaligner.com.
* MC-SE will be available after the appropriate registrations are received. Also, pending trademark registration
About Angelalign Technology Inc.
Founded in 2003 and publicly listed since 2021, Angelalign Technology Inc. provides clear aligner solutions to clinically focused professionals and patients in over 60 countries. Having surpassed two million cumulative cases and with about a US$2 billion market capitalization, the company focuses on clinical innovation and professional support to help experts achieve extraordinary outcomes. Its established global operations and continued investment in innovation support its long-term commitment to orthodontists and their patients. Learn more at angelaligner.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102654659/en/
Permalink
https://www.aetoswire.com/en/news/0311202658716
Contacts
Media Contact:
Sue Kolb
Angelalign Technology Inc.
sue.kolb@angelaligner.com
Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration
PALO ALTO, Calif. - Tuesday, 03. November 2026 AETOSWire
The AI-native collaboration platform reaches 320,000 users across 100+ countries, validates product-led growth and monetization, and prepares to expand its global AI agent ecosystem.
(BUSINESS WIRE) -- Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG).
32× Global Growth in One Quarter
Teamily AI grew from 10,000 to 320,000 registered users across more than 100 countries in one quarter, representing 32× growth and a 217.5% compound monthly growth rate.
According to publicly available Similarweb traffic, Teamily AI has surpassed the website traffic of several emerging AI agent platforms, including Town.com, Viktor.com, today.ai, and cue.im, companies that have reportedly raised $100 million to $400 million at billion-dollar valuations.
The company has observed consistent paid conversion across global markets, with the United States leading, followed by Europe and Chinese-speaking markets, and additional paying customers across South Asia, Africa, and Southeast Asia. This broad geographic adoption provides early validation of the global demand for AI-native collaboration and productivity.
Strong Monetization and Organic Team Adoption
Teamily AI has attracted several thousand paying customers and 20,000 daily active users. More than 10,000 company teams have connected coworkers on the platform, averaging six agent tasks per group per day, while users create more than 300 group-level agent automation loops daily.
Based on customer usage and payment behavior, Teamily has identified two major categories with strong product-market fit:
AI-powered collaboration: Group chat analysis, deep research, collaborative documents, meeting summaries, and multimodal file processing.
AI-powered creation: Website development, slides, image and video generation, and professional content creation.
These findings reinforce Teamily's focus on prosumers, teams, and small and medium-sized businesses (SMBs), supported by a product-led growth strategy.
The company's PLG funnel is also generating inbound enterprise opportunities. Teamily plans to expand its account executive and sales partner channels while offering enterprise customers private models, secure data integration, and hybrid workflows combining local agents with cloud-based frontier models.
Proprietary AI Infrastructure Enables Positive Unit Economics
Teamily AI has processed more than 100 million messages, approximately 35% generated by AI agents, creating a growing foundation of interaction data for improving model performance, inference efficiency, and cost optimization.
Unlike platforms that rely primarily on third-party model APIs, Teamily develops its own large language models and self-hosted inference infrastructure. Its optimized serving system has achieved 30% higher throughput than publicly reported vLLM/SGLang benchmarks, while maintaining positive gross margins on paying users.
Together, proprietary models, efficient infrastructure, and growing human–agent interaction data establish a self-reinforcing advantage in product quality and unit economics.
Expanding Monetization Beyond Subscriptions
Building on its subscription business, Teamily is exploring additional revenue models, including advertising, enterprise services, and agent-powered service distribution.
The company sees significant opportunities to connect users with relevant merchants and professional service providers through context-aware AI agents, potentially generating referral and transaction-based revenue.
Business services represent a particularly promising market, as AI agents could help companies discover, evaluate, and access specialized services more efficiently.
Looking Ahead: Building the Agentic Internet Ecosystem
With its global growth model and initial monetization strategy validated, Teamily AI is preparing to expand its ecosystem in the next phase of development.
The company's plans to release Teamily AI 3.0, a new version focusing on ecosystem strategy that includes wallet and merchant integrations, Studio plugins for high-value content creation, AI-native cloud storage connecting fragmented data sources, Mini Apps that turn third-party agentic applications into accessible AI agents, deeper app connectors, and expanded Channels that bring agents into external products.
Teamily also plans to strengthen partnerships with AI model developers, infrastructure providers, and data services, aiming to become a day-zero integration and distribution partner for emerging AI technologies.
"Our vision is to build the central platform of the next-generation Agentic Internet, where services and work are delivered by AI agents rather than confined to traditional applications," said Aiden Chaoyang He, Co-Founder and CEO of Teamily AI. "Just as Google transformed access to information in the web era, we believe AI agents will transform access to intelligence and services. Every user intent should be connected to the right people, agents, and services, with the right context and intelligence."
With strong initial commercial validation and a rapidly growing global user base, Teamily AI is preparing to accelerate growth in November while opening its platform to a broader ecosystem of businesses, vertical agent developers, and AI service providers.
About Teamily AI
Teamily AI is a human-agent platform where people and specialized AI agents share context and memory, collaborate on real work, and continuously learn and improve together. Built around an AI-native messenger, Teamily lets teams create custom agents, assemble them into agent teams, and put those teams to work producing websites, email, documents, presentations, video and images, inside the tools and channels where work already happens. Teamily AI publicly launched in July 2026 and was co-founded by Dr. Aiden Chaoyang He, formerly of Meta and Tencent, and Professor Salman Avestimehr, Dean's Professor at the University of Southern California, IEEE Fellow and PECASE recipient. The broader team brings together AI researchers, engineers, and product and growth veterans from Meta, Tencent, TikTok, Amazon, Google, Microsoft, and Qualcomm, combining deep AI expertise with proven experience in social networks, messaging platforms, consumer growth, and large-scale internet products. Teamily AI is headquartered in Palo Alto, California, the central hub of Silicon Valley. Learn more at https://teamily.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103047955/en/
Permalink
https://www.aetoswire.com/en/news/0311202658759
Contacts
For more information about Teamily AI, contact the company here:
Teamily AI
Kathy Liu
+1 (607) 319-1611
kathy@tensoropera.com
165 University Avenue, Palo Alto
Organigram to Acquire Aurora and Establish a Global Cannabis Leader
TORONTO & EDMONTON, Alberta - Tuesday, 03. November 2026 AETOSWire
(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”).
The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (“Curaleaf”) of its intention to launch a hostile takeover bid for Aurora (the “Unaffected Price”), and a 21% premium relative to the current bid value of the Curaleaf hostile offer3 (the “Hostile Bid”) as most recently amended on October 6, 2026, which was unanimously rejected by Aurora’s Board of Directors.
The Transaction provides Aurora shareholders with compelling immediate value, meaningful choice in how they receive their consideration, and the opportunity for continued participation in the future growth and value creation of the combined company.
Together, Organigram and Aurora will create a global cannabis champion with a leadership position in Canada, Europe and Australia and a growing presence across other key regions. The two Canadian-headquartered cannabis companies will boast a global platform with greater scale, broader capabilities, financial strength and international reach. Organigram’s recreational cannabis leadership, production network, R&D platform and European medical commercial operations complement Aurora’s global medical cannabis leadership, established international presence, and EU-GMP certified manufacturing capabilities. The combined company will also benefit from the support of Organigram’s cornerstone strategic shareholder, BT DE Investments Inc., a wholly-owned indirect subsidiary of British American Tobacco (“BAT”), a global consumer goods company with demonstrable innovation, marketing and product development capabilities around the world.
“This Transaction is a defining step in Organigram’s strategy to build a disciplined, global cannabis leader,” said James Yamanaka, CEO of Organigram. “By bringing together Aurora’s established global medical cannabis platform with our Canadian operations and growing international footprint, we are creating a larger, stronger, and more diversified company. We are excited to build on our complementary operations, expertise, capital resources, and cultures to accelerate growth, meet the growing global demand, and drive long-term profitable growth.”
“Combining with Organigram will accelerate Aurora’s international growth strategy by strengthening commercial execution, expanding our product and R&D capabilities, and extending our global operating network,” said Miguel Martin, Executive Chairman and CEO of Aurora. “For Aurora’s shareholders, the Transaction is the result of a robust strategic review process and delivers compelling value today, meaningful choice in how they receive it and the opportunity to participate in the future of a leading cannabis company.”
Compelling Strategic and Financial Rationale
Brings together highly complementary operations: Shareholders to benefit from a stronger platform resulting from the combination of Aurora’s EU-GMP certified manufacturing capacity and pharmacy and patient access network across Canada, Europe, Australia and New Zealand, and Organigram’s leading Canadian recreational brands and newly integrated Sanity Group’s European footprint.
Synergies: In excess of C$50 million in identified synergies from cross-selling across Organigram’s and Aurora’s Canadian and international footprints, procurement scale, consolidated distribution, public company expenses, and routing international demand to the lowest-cost production asset across the combined network.
Expands presence across world’s largest nationally regulated markets: Organigram shareholders to participate alongside Aurora shareholders in a company with greater scale, enhanced supply chain certainty and diversification. The company will have an enhanced presence across nationally legal cannabis markets, with established regulatory frameworks, licenses and infrastructure.
Accelerates product innovation and growth opportunities: The combined company’s scale and cross-border infrastructure create a platform for shared innovation and brand building, bolstered by Organigram’s strategic shareholder, BAT, which brings demonstrated expertise across R&D, innovative product development, and global supply chain management.
Preserves balance sheet strength: The cash component of the Consideration is fully financed and expected to be financed through cash on hand, a concurrent investment by BAT and an increase in Organigram’s existing credit facility, preserving Organigram and Aurora’s disciplined, balanced approach between efficient capital allocation and driving sustained profitable growth. The financing structure is designed to preserve balance sheet flexibility and support continued investment in the combined company’s growth priorities.
Enhanced liquidity and capital markets profile: The acquisition will result in a larger market capitalization and increased free float. Index eligibility is expected to broaden the institutional shareholder base and support improved trading liquidity and research coverage. Greater scale, certified international supply and a diversified revenue base will make the combined entity the clear strategic counterparty in the sector for global CPG and pharmaceutical partners.
Provides choice for Aurora shareholders: The Transaction provides Aurora shareholders with flexibility in how they receive the premium in exchange for their Aurora Shares. Aurora shareholders can choose between an attractive mix of cash or Organigram Shares, or a combination of both.
Creates meaningful equity participation for Aurora shareholders: Aurora shareholders are expected to hold approximately 35% pro forma economic ownership of the combined company on a fully diluted basis and 42% voting ownership, ensuring a meaningful opportunity to participate in the combined company’s future growth and value creation.
Transaction Details
Under the terms of the Arrangement Agreement, Aurora shareholders will have the option to elect to receive:
C$7.80 per Aurora Share in cash (the “Cash Consideration”);
5.8626 common shares in the capital of Organigram (the “Organigram Shares”) per Aurora Share (the “Share Consideration”); or
a combined consideration of C$3.75 in cash plus 3.0431 Organigram Shares (the “Combined Consideration”), in each case per Aurora Common Share (collectively, the “Consideration”).
Aurora shareholders electing to receive the Cash Consideration or the Share Consideration will be subject to proration as set out in the Arrangement Agreement so that the aggregate consideration will include no more than 205,826,172 Organigram Shares and no more than C$253,638,772 in cash. Based on the 20-day volume-weighted average trading price of Organigram Shares on the TSX of approximately C$1.33 on November 2, 2026, the Consideration represents C$7.80 per Aurora Common Share.
The Transaction will be carried out by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) and is subject to the following approvals:
At least two-thirds of the votes cast by Aurora shareholders present in person or represented by proxy at a special meeting of Aurora shareholders (the “Aurora Meeting”); and
A simple majority of the votes cast by Aurora shareholders present in person or represented by proxy at the Aurora Meeting, excluding votes from certain shareholders, as required under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”).
The issuance of Organigram Shares pursuant to the Transaction and Private Placement (defined below) is subject to the approval by a simple majority of votes cast by Organigram shareholders at a special meeting of Organigram shareholders, excluding votes held by BAT, as required under MI 61-101 and the rules of the TSX.
Details of the Transaction and the required shareholder votes will be included in a joint information circular that Organigram and Aurora expect to mail to their respective shareholders in due course. The special meetings for Organigram shareholders and Aurora shareholders are expected to be held in December 2026.
BAT, which is entitled to cast 30% of the votes attaching to Organigram Shares, has entered into an irrevocable voting agreement agreeing to vote its Organigram Shares in favour of the Transaction and against any competing acquisition proposals. The voting agreement with BAT will not be terminable until six months following termination of the Arrangement Agreement in certain circumstances. In addition, each of the other directors and officers of each of Aurora and Organigram have entered into customary voting agreements agreeing to vote their Aurora Shares or Organigram Shares in favour of the Transaction. The voting and support agreements with directors and officers will terminate automatically upon termination of the Arrangement Agreement.
In addition to the shareholder approvals, the Transaction will be subject to regulatory approvals, as well as the approval of the Supreme Court of British Columbia. Subject to the satisfaction of such conditions, the Transaction is expected to be completed in January 2027.
The Transaction would be structured to provide a tax-deferred rollover to eligible Canadian-resident Aurora shareholders who receive Organigram Shares, subject to applicable law and advice from their own tax advisors.
BAT Concurrent Private Placement / Financing
In connection with financing the Transaction and concurrently with the closing of the Transaction, BAT will acquire, on a private placement basis (the “Private Placement”), 141.0 million Organigram Shares at a price of C$1.33 per share for gross proceeds of £0.70926 (or C$1.33 based on the GBP/CAD exchange rate on November 2, 2026) million for total gross proceeds of £100,000,000 (or C$187.5 million based on the GBP/CAD exchange rate on November 2, 2026) (the “Private Placement Proceeds”) pursuant to the terms of a subscription agreement dated November 2, 2026 (the “Subscription Agreement”). To the extent BAT’s ownership of Organigram Shares in Organigram exceeds 30.0% of the total issued and outstanding Organigram Shares on a post-issuance basis (the “30% Threshold”), BAT would, in lieu of Organigram Shares, be issued non-voting Class A convertible preferred shares of Organigram (the “Preferred Shares”). The Private Placement Proceeds will be used to finance the cash portion of the Consideration and certain related transaction expenses of Organigram. The Preferred Shares are eligible for conversion into Organigram Shares in accordance with their terms, provided that such conversion would not result in ownership by BAT or its affiliates, associates, related parties and any joint actors exceeding 30.0% of the total issued and outstanding Organigram Shares on a post-conversion basis.
ATB Financial Senior Secured Credit Facilities
ATB Financial ("ATB") has provided a fully committed and underwritten commitment for senior secured credit facilities of up to $210 million (the "Loan Facilities"). The Loan Facilities will be established by amending and restating Organigram's existing $70 million senior secured credit agreement with ATB. ATB alone is providing the full commitment, as lead arranger and sole bookrunner. ATB's commitment is not conditional on syndication. ATB may syndicate a portion of the Loan Facilities to other lenders, who may become party to the credit agreement from time to time. ATB will also act as administrative agent for the Loan Facilities.
The Loan Facilities include:
A $10 million senior secured revolving operating credit facility, provided by ATB;
A $65 million senior secured revolving credit facility (the "Revolving Facility"), provided initially by ATB and, after any syndication, by such other lenders as may become party to the credit agreement from time to time. Up to $35 million of the Revolving Facility may, subject to certain conditions, be used to partially finance the acquisition of Aurora; and
A $135 million senior secured non-revolving term credit facility (the "Term Facility"), provided initially by ATB and, after any syndication, by such other lenders as may become party to the credit agreement from time to time. The Term Facility has two tranches:
"Term Tranche 1", in the amount of $20 million, which was drawn in full to finance the acquisition of Sanity Group and remains outstanding; and
"Term Tranche 2", in the amount of $115 million, which will be available on the Closing Date to partially finance the acquisition of Aurora.
The amended and restated Loan Facilities will be available on the Closing Date. Availability is subject only to a limited set of conditions precedent, customary for acquisition financings on a "certain funds" basis. These include completion of the acquisition substantially at the same time as funding, receipt of the final order approving the arrangement, receipt of the committed equity proceeds, and the accuracy of certain specified representations. The Loan Facilities will mature three years after closing and bear interest at ATB's applicable benchmark rates plus an applicable margin based on the ratio of net funded debt to EBITDA. The Loan Facilities will be subject to customary financial covenants, including a maximum net funded debt to EBITDA ratio and a fixed charge coverage ratio.
Superior Alternative for Aurora Shareholders to the Hostile Bid
The Transaction emerged from a robust strategic review process conducted by Aurora, under the oversight of a committee of independent directors (the “Aurora Special Committee”), advised by independent legal and financial advisors. The review process involved an extensive market check, including outreach to multiple parties, in connection with the unanimous rejection of the Hostile Bid, as detailed in the Notice of Change to Aurora’s Directors’ Circular dated October 14, 2026. The Aurora Special Committee and the Board of Directors of Aurora (the “Aurora Board”) believe that the Transaction is superior to the Hostile Bid and the best actionable path forward to maximize value for Aurora shareholders.
The Aurora Special Committee and the Aurora Board continue to reiterate that the Hostile Bid is not in the best interests of Aurora or its shareholders and unanimously recommend that shareholders REJECT the Hostile Bid by taking no action and DO NOT TENDER their Aurora Shares to the Hostile Bid. Aurora intends to file a second Notice of Change to its Directors’ Circular confirming the Aurora Board’s continued recommendation to reject the Hostile Bid and vote in favour of the Transaction (the “Second Notice of Change”), which will be made available on Aurora’s SEDAR+ profile at www.sedarplus.ca and on EDGAR at www.sec.gov.
Aurora Shareholders who have already tendered their Aurora Shares to the Unsolicited Curaleaf Hostile Offer can withdraw their Aurora Shares by contacting their broker or Kingsdale Advisors by toll free phone call in North America to 1-800-749-9052, or call or text: 416-623-4172 or by email at contactus@kingsdaleadvisors.com.
Unanimous Board Approvals and Recommendations
The Transaction and the Private Placement were unanimously approved (with BAT’s nominees to the Board abstaining from the vote with respect to the Private Placement) by the Board of Directors of Organigram (the “Organigram Board”), after receiving a recommendation from the Investment Committee of the Organigram Board (the “Investment Committee”). The Investment Committee and the Organigram Board have unanimously determined that the Transaction and the Private Placement are in the best interests of Organigram.
In connection with Organigram’s review and consideration of the Transaction, BMO Capital Markets has provided an opinion to the Investment Committee and the Organigram Board to the effect that, as of the date of such opinion, and subject to the assumptions, limitations and qualifications to be set forth in its written opinion, the Consideration to be paid by Organigram pursuant to the Arrangement Agreement is fair, from a financial point of view, to Organigram.
The Transaction was unanimously approved by the Aurora Board, after receiving a unanimous recommendation from the Aurora Special Committee. The Special Committee and the Aurora Board determined that the Transaction is in the best interests of Aurora, and the Aurora Board is recommending that Aurora shareholders vote in favour of the Transaction.
In connection with Aurora’s review and consideration of the Transaction, Fort Capital and Origin Merchant Partners have each provided an opinion to the Aurora Special Committee and the Aurora Board to the effect that, as of the date of such opinion, and subject to the assumptions, limitations and qualifications to be set forth in its written opinion, the Consideration to be received by Aurora shareholders pursuant to the Arrangement Agreement is fair, from a financial point of view, to such shareholders.
A copy of the Arrangement Agreement and the joint information circular with respect to the Transaction will be filed on Organigram’s and Aurora’s respective SEDAR+ profiles and will be available for viewing at www.sedarplus.ca and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov).
Advisors and Counsel
BMO Capital Markets is serving as the financial advisor to Organigram in respect of the Transaction and has provided a fairness opinion to the Investment Committee and the Organigram Board. Goodmans LLP is serving as legal advisor to Organigram.
Fort Capital Partners is serving as financial advisor to Aurora in respect of the Transaction and has provided a fairness opinion. Origin Merchant Partners is serving as financial advisor to the Aurora Special Committee and has provided a fairness opinion. Legal counsel to the Aurora Special Committee is Torys LLP. Legal counsel to Aurora is Stikeman Elliott LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP.
Osler, Hoskin & Harcourt LLP is serving as legal counsel to BAT.
To learn more about the Organigram-Aurora Transaction, visit www.OrganigramXAurora.com and www.VoteYesAurora.com.
About Organigram
Organigram Global Inc. is listed on the NASDAQ Global Select Market and TSX. The Company's wholly owned subsidiary, Organigram Inc., is a licensed cultivator and processor. Through its acquisition of Sanity Group GmbH ("Sanity Group"), Organigram participates in the German medical cannabis market and other emerging markets within Europe. Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, ZOIKS, Endosane Pharmaceuticals, VAAY, and Grashaus Projects. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Contacts
Aurora has filed a Solicitation/Recommendation Statement on Schedule 14D-9F with the U.S. Securities and Exchange Commission (the “SEC”), which includes a Directors’ Circular, dated September 1, 2026, as amended by the Notice of Change of Aurora dated October 14, 2026. Investors are urged to read this document and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, when they become available, before making any investment decision with respect to the Hostile Bid. The Hostile Bid is made for the securities of a Canadian issuer and while the Hostile Bid is subject to disclosure requirements of Canada, investors should be aware that these requirements are different from those of the United States. The enforcement by investors of civil liabilities under the U.S. federal securities laws may be affected adversely by the fact that the issuer is located in Canada, and that some or all of its officers and directors are residents of Canada.
Forward-Looking Information
This news release contains certain forward-looking statements and forward-looking information (collectively, "forward-looking statements"), including forward-looking statements within the meaning of the "safe harbor" provisions of applicable securities legislation, that are based on Organigram’s and Aurora's current expectations, estimates, projections and assumptions in light of their experience and their perception of historical trends. In some cases, forward-looking statements can be identified by terminology such as "expects", "will", "would", "anticipates", "plans", "estimates", "develop", "intends", "potential", "continue", "could", "create", and similar expressions suggesting future events or future performance. Forward-looking statements are often, but not always, identified by such words. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements.
In particular, this news release contains forward-looking statements, including certain financial outlooks, pertaining to, without limitation, the following: the Transaction; the anticipated closing date and the anticipated benefits of the Transaction to Organigram’s and Aurora’s respective securityholders and stakeholders; the Consideration to be received by Aurora’s shareholders pursuant to the Transaction; the number of Organigram Share and Preferred Shares to be issued in respect of the Private Placement; the terms of the Private Placement; Organigram’s shareholders’ level of ownership in the combined company following closing of the Transaction; Organigram’s ability to finance the Transaction, including by way of the Private Placement and through Organigram’s existing credit facility; the anticipated operational and strategic benefits of the Transaction; the expected size, cash flow, growth and capacity of the combined company; the respective aggregate shareholdings of Organigram and Aurora shareholders in the combined company following the completion of the Transaction; the anticipated risks and results of accepting the Hostile Bid; management of the combined company; the anticipated timing and the contents of mailing the joint information circular regarding the Transaction; the anticipated timing of the special meetings of the shareholders of Aurora and Organigram.
Forward-looking statements also include, without limitation, the inherent uncertainty associated with the financial and other projections contained in this news release (including projections relating to revenue, enhanced liquidity and valuation) and the anticipated C$50 million in identified synergies resulting from the Transaction, including savings from cross-selling across Organigram’s and Aurora’s Canadian and international market, procurement scale, consolidated distribution, expenses and routing international demand across a combined company network.
These forward-looking statements are based on certain assumptions and analysis, including, among other things: the ability of the parties to satisfy the conditions to closing of the Transaction in a timely manner and substantially on the terms described in this news release; that the Transaction will be completed in the timelines and on the terms currently anticipated; that the Transaction will receive the requisite shareholder approval at the special meetings of the shareholders of Organigram and Aurora; that Organigram shareholders will vote to approve the Private Placement at the special meeting of Organigram shareholders; that a significant number of Aurora Shares are not tendered to the Hostile Bid; that all necessary court, stock exchange and regulatory approvals will be obtained on the necessary terms and in a timely manner, including all necessary regulatory approvals in Germany; that Organigram will come to terms with BAT in respect of the Private Placement; that the conditions to closing the Private Placement and receipt of funding under Organigram’s existing credit facility will be satisfied within a reasonable period of time or at all; the availability of capital to fund future capital requirements; that the combined company's future results of operations will be consistent with past performance and management expectations in relation thereto; general assumptions respecting the business and operations of both Organigram and Aurora, including that each business will continue to operate in a manner consistent with past practice; that the anticipated C$50 million in run rate cost synergies will result in savings in respect of the combined company’s future operations; prevailing regulatory, tax and environmental laws and regulations; interest rates, tax rates and foreign exchange rates; future capital and other expenditures; future operating costs; that counterparties will comply with contracts in a timely manner; that there are no unforeseen events preventing the performance of contracts; the amount of any future liabilities from litigation and environmental incidents; and the impact of increasing competition on the combined company.
Although Organigram and Aurora believe the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the ability of the parties to receive, in a timely manner, the necessary regulatory, court, securityholder, stock exchange and other third-party approvals, including but not limited to approval from the TSX and foreign direct investment clearance from the German Federal Ministry for Economic Affairs and Energy required to close the Transaction; the timing and outcome of any such regulatory review negatively impacting the Transaction; the ability of the parties to satisfy, in a timely manner, the other conditions to the closing of the Transaction; the failure to realize the anticipated benefits or $50 million in anticipated run rate cost synergies of the Transaction following closing due to integration issues or otherwise and expectations and assumptions concerning, among other things: customer demand for the combined company's products and services; interest and foreign exchange rates; planned synergies, capital efficiencies and cost-savings; applicable tax laws; labour and material shortages; non-performance or default by counterparties to agreements which Organigram or one or more of its affiliates has entered into in respect of its business; the impact of competitive entities and pricing; reliance on key relationships and agreements; actions by governmental or regulatory authorities, including changes in tax laws and treatment; fluctuations in operating results; adverse general economic and market conditions in Canada, Germany and worldwide, including changes, or prolonged weaknesses, as applicable, in interest rates, foreign currency exchange rates, and overall industry activity levels; the political environment in North America and Europe, and public opinion; ability to access various sources of debt and equity capital; counterparty credit risk; technology and cyber security risks; natural catastrophes; and certain other risks detailed from time to time in Organigram 's public disclosure documents available at www.sedarplus.com, www.sec.gov and through Organigram 's website at www.organigram.ca and in Aurora's public disclosure documents available at www.sedarplus.com, www.sec.gov and through Aurora's website at www.auroramedical.com. In addition, the closing of the Transaction may not be completed, or may be delayed if the parties' respective conditions to the closing of the Transaction, including the timely receipt of all necessary regulatory approvals, are not satisfied on the anticipated timelines or at all. Accordingly, there is a risk that the Transaction will not be completed within the anticipated time, on the terms currently proposed and disclosed in this news release or at all.
This list of risk factors should not be construed as exhaustive. Readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward-looking statements contained in this news release speak only as of the date of this news release. Neither Organigram nor Aurora undertakes any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Required Early Warning Disclosure
The Private Placement Shares will be issued directly from treasury, and accordingly, the Private Placement does not constitute a take-over bid under National Instrument 62-104 – Take-Over Bids and Issuer Bids. The Private Placement Shares are being issued in reliance on the accredited investor exemption under section 2.3 of National Instrument 45-106 – Prospectus Exemptions.
The following table illustrates BAT’s current shareholdings in Organigram, as well as its expected shareholdings in Organigram on completion of the Private Placement and Transaction. The following figures are basic only (except where otherwise indicated) and are based on Organigram Shares issued and outstanding as of November 2, 2026. The following figures are presented and calculated in accordance with, and provided for purposes of compliance with, National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”) and Form 62-103F1 – Required Disclosure Under the Early Warning Requirements.
Holdings (% of class)
Current
(November 2, 2026)
Private Placement
Pro-Forma Private Placement + Transaction **±
BAT Common Share Holdings
42,231,089
(30%)
95,397,664
143,142,947
(30%)
BAT Preferred Share Holdings
49,204,021
(100%)
45,594,817
94,798,839
(100%)
BAT Common and Preferred Share Holdings (including accretion on Preferred Shares and partially diluted to assume conversion of Preferred Shares)
94,688,693
(49%)
144,246,063
241,195,368
(42%)
**Assumes the issuance of the maximum of 205,826,172 Organigram Shares to Aurora shareholders under the Transaction and the exchange rate described above.
± Assumes the issuance of the maximum of 5,514,194 Organigram Shares to the sellers in connection with Organigram’s previously completed acquisition of Sanity Group GmbH.
BAT intends to review its investment in Organigram on a continuing basis and may, subject to the terms of the Second A&R Investor Rights Agreement and the Amendment to the Second A&R Investor Rights Agreement (each as defined below), and depending upon a number of factors, including market and other conditions, increase or decrease its beneficial ownership, control, direction or economic exposure over securities of Organigram, through market transactions, private agreements, treasury issuances, exercise of options, convertible securities, derivatives, swaps or otherwise.
Unless otherwise consented to in writing by BAT in advance, Organigram is required to use the proceeds from the Private Placement for the sole purpose of (a) funding a portion of the aggregate Cash Consideration and other amounts payable by Organigram under the Arrangement Agreement and (b) paying transaction expenses in connection with the Private Placement and the Transaction.
Pursuant to the second amended and restated investor rights agreement entered into on April 15, 2026, between BAT and Organigram (the “Second A&R Investor Rights Agreement”), BAT has the right to nominate up to 30% of the Organigram Board, subject to BAT maintaining certain share ownership thresholds. BAT is entitled, subject to the terms and conditions of its nomination rights, to replace its nominee directors from time to time. In addition, BAT has certain governance rights, so long as it maintains certain share ownership thresholds, including pre-emptive rights, top-up rights and customary registration rights. BAT is permitted to engage with the Organigram Board regarding Organigram’s business and prospects.
On closing of the Private Placement, Organigram and BAT intend to enter into an amendment to the Second A&R Investor Rights Agreement (the “Amendment to the Second A&R Investor Rights Agreement”) to amend certain provisions of the Second A&R Investor Rights Agreement in order to, among other things, clarify the terms of BAT’s pre-emptive and top-up rights. The terms of the Amendment to the Second A&R Investor Rights Agreement will be negotiated between Organigram and BAT prior to the concurrent closing of the Private Placement and the Transaction.
The foregoing is a summary only and is qualified in its entirety by reference to the full text of the Subscription Agreement and the Arrangement Agreement, each of which will be filed under Organigram’s profile on SEDAR+ at www.sedarplus.ca.
Organigram is a corporation existing under the laws of Canada with its head office at 145 King Street West, Suite 1400, Toronto, Ontario, Canada, M5H 1J8. BAT is a corporation incorporated under the laws of Delaware and is a wholly-owned indirect subsidiary of British American Tobacco p.l.c. (LSE: BATS and NYSE: BTI). The address of BAT is 103 Foulk Road, Suite 111, Wilmington, Delaware, 19803.
This press release is being issued, in part, pursuant to NI 62-103, which requires an early warning report to be filed under Organigram’s profile on SEDAR+ at www.sedarplus.ca containing additional information respecting the foregoing matters. You may also contact BAT’s media centre at +44 (0) 20 7845 2888, Victoria Buxton at +44 (0) 20 7845 2012 or Amy Chamberlain at +44 (0) 20 7845 1124 to obtain a copy of the early warning report once filed.
1 The day prior to the announcement by Curaleaf of its intention to launch a hostile takeover bid for Aurora.
2 Based on the 20-day VWAP of Curaleaf shares traded on the TSX on November 2, 2026, and assuming a USD/CAD exchange rate of 1.4115, calculated as the 20-trading day average exchange rate.
3 Based on the 20-day VWAP of Curaleaf shares traded on the TSX on November 2, 2026, and assuming a USD/CAD exchange rate of 1.4115, calculated as the 20-trading day average exchange rate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103746636/en/
Permalink
https://www.aetoswire.com/en/news/54634260
Contacts
Organigram
For North American Media: Media@organigram.ca
For European Media: Euro.media@organigram.ca
For Investors:
Max Schwartz, Director of Investor Relations
investors@organigram.ca
Organigram shareholders with questions about the Transaction announced today, or who would like to stay informed, may contact Sodali & Co, Organigram’s strategic shareholder advisor and proxy solicitation agent:
North American Toll-Free Number: 1-833-830-9806
Outside North America, Banks, Brokers and Collect Calls: 1-289-695-3075
Email: assistance@investor.sodali.com
Aurora
For Media:
Michelle Lefler, VP, Communications & PR
media@auroramj.com
For Investors:
ICR, Inc., Investor Relations
Aurora@icrinc.com
Aurora shareholders with questions about the Transaction announced today, Curaleaf’s Hostile Bid or who would like to stay informed may contact Kingsdale Advisors, Aurora’s strategic advisor and information agent:
Toll-Free (within North America): 1-800-749-9052
Call or Text: 416-623-4172
Email: contactus@kingsdaleadvisors.com
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI
CHICAGO -
Report details NIQ’s continued focus on responsible business, including its first climate risk assessment, expanded employee development and more than 100,000 volunteer hours
(BUSINESS WIRE)--NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI.
Key highlights from 2025 include:
Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint.
Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance review completion reached 99% and the employee survey response rate reached 89%. NIQ also introduced three new leadership development tracks, while Employee Assistance Program utilization increased from 5.9% to 28.8%.
Expanded community and inclusion impact: More than 12,000 NIQ associates contributed over 100,000 volunteer hours across more than 565 People & Planet Day activities. NIQ’s Employee Resource Groups included more than 3,000 members across 85+ countries, supported by more than 50 Inclusion Impact Teams.
Advanced data integrity and responsible AI governance: NIQ continued to build out its AI governance framework, guided by a Global AI Policy and cross-functional oversight from Legal, Privacy, Security, and Technology teams. This approach supports the responsible use of AI across data collection, processing, and client-facing tools.
“At NIQ, accelerating growth for our customers goes hand in hand with creating positive outcomes for the world around us,” said Jim Peck, Executive Chairman and CEO of NIQ. “We’re building on strong momentum, using our intelligence and innovation to create meaningful, long-term value for our clients, our people, and the communities we serve.”
Frequently Asked Questions
What is NIQ’s 2026 ESG Progress Report?
The NIQ 2026 ESG Progress Report provides an overview of the company’s environmental, social and governance priorities, actions and performance throughout 2025, including progress across environmental responsibility, people and culture, community impact, data integrity, and responsible AI governance.
What ESG progress did NIQ make in 2025?
In 2025, NIQ advanced its ESG priorities across several areas, including conducting its first climate risk assessment, expanding employee development and engagement programs, contributing more than 100,000 volunteer hours through People & Planet Day activities, and continuing to strengthen its approach to data integrity and responsible AI governance.
How is NIQ addressing climate risk and environmental responsibility?
NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations. The company also continued to track Scope 1, 2, and 3 greenhouse gas emissions under the GHG Protocol and externally verified its carbon footprint.
How does NIQ approach responsible AI and data governance?
NIQ’s approach to responsible AI is guided by its Global AI Policy and cross-functional governance involving Legal, Privacy, Security and Technology teams. This framework supports responsible AI use across data collection, processing, and client-facing tools.
About NIQ’s Environmental, Social and Governance Report
NIQ’s 2026 ESG Progress Report details the company’s ESG approach and performance throughout 2025. NIQ’s reporting approach aligns with recognized global frameworks, including the United Nations Sustainable Development Goals (UN SDGs), Global Reporting Initiative (GRI), and Sustainability Accounting Standards Board (SASB). Read the full report here.
About NIQ
NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.
With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.
For more information, please visit www.niq.com
NIQ-IR
Forward-Looking Statements
This press release contains “forward-looking statements,” including statements about anticipated timelines, benefits, features, and outcomes of the agreement. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Forward-looking statements speak only as of the date made and NIQ undertakes no obligation to update them except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102627326/en/
Permalink
https://aetoswire.com/en/news/54629743
Contacts
Media Contact: media.relations@nielseniq.com
Subscribe to:
Posts (Atom)